Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
robatumumab + trastuzumab
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
robatumumab + trastuzumab is an experimental combination of two monoclonal antibodies. **Robatumumab** is a fully human monoclonal antibody targeting the type I insulin-like growth factor 1 receptor (IGF-1R), developed to inhibit growth and survival signals in tumors dependent on IGF-1R signaling. **Trastuzumab** is a humanized anti-HER2 monoclonal antibody that inhibits HER2/neu (ERBB2) signaling, primarily used as targeted therapy in HER2-positive breast and gastric cancers. This combination is likely designed to simultaneously block two major oncogenic pathways—IGF-1R and HER2—potentially overcoming resistance seen with trastuzumab monotherapy. The combination has been investigated at the preclinical and early-phase clinical trial level for overcoming trastuzumab resistance, particularly in metastatic HER2-positive breast cancer[1].
- Brand names
- Herceptin (for trastuzumab)
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on robatumumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on robatumumab + trastuzumab.